TRT and Type 2 Diabetes Prevention What 8-Year and RCT Data Show

Estimated reading time: 9 minutes

Key takeaways

An 8-year registry in hypogonadal men with prediabetes reported zero progression to type 2 diabetes on long-term TRT; untreated men progressed as expected (observational evidence).
The randomized T4DM trial showed a 41% lower risk of developing diabetes over two years with TRT plus lifestyle versus lifestyle alone.
TRT improves insulin sensitivity, glucose uptake, and often lipids and inflammation; benefits are not fully explained by weight loss alone.
TRAVERSE found no excess major cardiovascular events versus placebo, but monitoring remains essential—especially for hematocrit and prostate parameters.
Best fit: men with confirmed hypogonadism and prediabetes or metabolic syndrome features, using TRT to complement lifestyle changes.

Introduction
The 8-year signal: complete prevention of prediabetes-to-diabetes progression
Randomized evidence: T4DM trial shows 41% lower diabetes risk over two years
What improves metabolically on TRT—and why
Safety: cardiovascular events, hematocrit, and prostate monitoring
Who might benefit most—and who should be cautious
Practical implications if you’re considering TRT for metabolic risk
Where GLP-1 medications fit alongside testosterone
What remains uncertain—and what to watch next
Conclusion

Introduction

Testosterone replacement therapy (TRT) is best known for addressing symptoms of hypogonadism—low testosterone confirmed on repeat testing. But an emerging body of evidence suggests it may also help prevent progression from prediabetes to type 2 diabetes (T2DM) in select men when paired with lifestyle changes. One long-term registry reported complete prevention of diabetes progression over eight years among hypogonadal men on TRT. At the same time, high-quality randomized data show meaningful reductions in diabetes risk over two years. This article examines what those results mean, the potential mechanisms, and the necessary cautions.

The 8-year signal: complete prevention of prediabetes-to-diabetes progression

In an 8-year registry study of hypogonadal men with prediabetes receiving long-term injectable testosterone undecanoate, Yassin and colleagues reported a striking outcome: none of the treated men progressed to type 2 diabetes over follow-up, while progression occurred in the untreated group. Related long-term analyses from the same registry also suggested lower all-cause mortality and fewer nonfatal myocardial infarctions among those treated, and a subset of men with established diabetes achieved remission over 12 years.

Why this matters:

It suggests TRT could stabilize or reverse metabolic deterioration in men with low testosterone, at least within the context of comprehensive care.
It aligns with physiological data showing testosterone’s role in glucose metabolism and insulin signaling.

Important caveats:

The study was observational. Men who persisted with TRT over many years may also adhere better to nutrition, exercise, sleep, and clinic follow-up, all of which strongly affect diabetes risk.
Treatment protocols, patient selection, and ancillary care can vary across centers and time.

Bottom line: The “complete prevention” finding is attention-grabbing and clinically encouraging, but it does not, on its own, prove TRT prevents diabetes in all similar men. It does, however, justify serious consideration of metabolic benefits when treating hypogonadal men at high risk.

Randomized evidence: T4DM trial shows 41% lower diabetes risk over two years

The T4DM study provides rigorous, placebo-controlled evidence. In more than 1,000 men aged 50–74 with impaired glucose tolerance or newly diagnosed T2DM, a structured lifestyle program was paired with either TRT or placebo for two years. Compared with lifestyle alone, TRT led to:

41% relative risk reduction in progression to type 2 diabetes
A larger mean decline in 2-hour oral glucose tolerance test (OGTT) glucose
Improvements that extended beyond what lifestyle changes alone achieved

Clinical interpretation:

In appropriately selected older men with low–normal testosterone and impaired glucose tolerance, TRT can meaningfully reduce diabetes progression risk over two years.
T4DM was not designed to assess outcomes beyond two years, so durability is uncertain.
Hematocrit elevations were a meaningful, treatment-limiting side effect—reinforcing the need for systematic monitoring.

What improves metabolically on TRT—and why

1) Insulin sensitivity and glucose uptake

Clamp studies reported approximately 32% increases in glucose uptake after several months of TRT in hypogonadal men.
Meta-analyses show consistent improvements in fasting glucose, fasting insulin, and HOMA-IR, along with a modest average HbA1c reduction (~0.29%).

2) Body composition and muscle function

Testosterone supports lean mass accrual and may promote more effective glucose disposal by skeletal muscle.
Metabolic benefits often exceed what would be expected from weight changes alone.

3) Inflammation and lipid profile

Reduced inflammatory activity has been described in long-term cohorts.
Improved lipid parameters—lower total cholesterol, triglycerides, and LDL, and higher HDL—may indirectly influence insulin signaling and vascular health.

These mechanisms are interrelated. In practice, men often report better energy and exercise capacity on TRT, which may accelerate adherence to lifestyle interventions—an underappreciated synergy in real-world settings.

Safety: cardiovascular events, hematocrit, and prostate monitoring

Cardiovascular safety

Earlier retrospective studies produced conflicting signals about cardiovascular risk.
The FDA-mandated TRAVERSE trial (AndroGel 1.62%) demonstrated non-inferiority to placebo on major adverse cardiovascular events, with near-identical rates over follow-up (7.0% TRT vs. 7.3% placebo). No new safety signals emerged.
Generalizability remains a consideration: TRAVERSE enrolled relatively healthy men. Whether results hold in older or higher-risk populations still needs study. FDA labeling continues to advise caution.

Hematocrit elevation

TRT commonly raises hematocrit. In T4DM, this was specifically noted as treatment-limiting.
Elevated hematocrit can increase thromboembolic risk; standardized monitoring is a core part of safe TRT practice.

Prostate considerations

Long-term, definitive data on prostate cancer risk remain limited, though recent studies have not shown an excess signal during trial timeframes.
Common practice includes baseline PSA with periodic monitoring per guidelines and shared decision-making.

The take-home: The evolving evidence supports careful, individualized use with structured monitoring and open discussion of benefits and risks.

Who might benefit most—and who should be cautious

Most applicable candidates based on current evidence

Men aged roughly 50–74 with confirmed hypogonadism (low testosterone on at least two morning tests) and impaired glucose tolerance or early type 2 diabetes
Overweight or obese men with metabolic syndrome features (elevated fasting glucose, central adiposity, dyslipidemia), especially if lifestyle efforts are underway

Caution or exclusion often applies to

Men with active or high-risk prostate cancer
Those with markedly elevated hematocrit at baseline
Men with recent major cardiovascular events, uncontrolled severe sleep apnea, or other contraindications identified by their clinician

This is not a one-size-fits-all intervention. The promise of “TRT prevents type 2 diabetes” is most relevant to a subset of hypogonadal men whose metabolic risk is already high—and who are also willing to engage in diet, activity, and follow-up.

Practical implications if you’re considering TRT for metabolic risk

For clinicians

Confirm biochemical hypogonadism on repeat morning testing and correlate with symptoms.
Discuss evidence that TRT can reduce diabetes progression risk in high-risk men when combined with lifestyle changes, referencing both RCT and long-term registry data.
Review the evolving cardiovascular safety profile, persistent FDA cautions, and the need for hematologic and prostate monitoring at defined intervals.
Set expectations: TRT is complementary to lifestyle, not a replacement.

For patients

View TRT as one component of a broader plan that includes nutrition, physical activity, sleep quality, and stress management.
Expect ongoing lab monitoring and follow-ups; this is how benefits are maintained and risks mitigated.
Report any new symptoms (e.g., excessive fatigue, shortness of breath, headaches) that could suggest hematocrit elevation or other concerns.

How Taurus Meds can help

Our approach emphasizes appropriate diagnosis, shared decision-making, and structured monitoring. If you have prediabetes or metabolic syndrome and suspect low testosterone, a conversation with a clinician experienced in both hormone and metabolic health can clarify your options.

Where GLP-1 medications fit alongside testosterone

GLP-1 receptor agonists (e.g., semaglutide) have transformed obesity and diabetes care. Early evidence suggests these agents may raise testosterone in men with obesity-related hypogonadism while preserving gonadotropin function.

GLP-1RAs can improve weight, glycemia, and inflammatory tone—factors that also influence testosterone and insulin sensitivity.
It’s not yet clear whether combining GLP-1RAs with TRT provides additive or synergistic benefits on diabetes prevention, body composition, or reproductive endpoints.
Trials are underway to compare or combine these strategies, including studies focused on functional hypogonadism and sperm quality.

For now, GLP-1RAs and TRT may serve overlapping but distinct roles, chosen based on individual priorities (weight loss, fertility considerations, symptom burden) and clinical findings.

What remains uncertain—and what to watch next

Durability: T4DM shows clear benefits through two years; longer-term randomized data are still needed to confirm sustained diabetes prevention.
Which men respond best: Predictors of remission or robust glycemic response remain unclear. Personalized approaches and combination strategies may enhance outcomes.
Cardiovascular generalizability: TRAVERSE is reassuring, but high-risk populations need further study.
Standardized biomarker panels: Inflammation and other mechanistic markers deserve consistent measurement in future trials to clarify pathways.
Formulations and dosing: Whether injections, gels, patches, or orals offer equivalent metabolic benefits and tolerability is not fully established across diverse populations.

Conclusion

For men with confirmed hypogonadism and prediabetes or early T2DM, the idea that TRT prevents type 2 diabetes is backed by encouraging evidence—most notably, a randomized trial demonstrating a 41% reduction in progression over two years, and an 8-year registry reporting no progression among treated men. The likely drivers include improved insulin sensitivity, better glucose disposal, and favorable shifts in inflammation and lipids.

Yet caution is appropriate. The most dramatic long-term findings are observational, and safety requires structured monitoring—particularly of hematocrit and prostate parameters. Cardiovascular reassurance from TRAVERSE is meaningful but not definitive for every patient profile.

In practice, TRT is best considered as part of a comprehensive plan that prioritizes lifestyle change. For the right patient, it can be a clinically meaningful lever against diabetes progression. The decision should be collaborative, rooted in the lab-confirmed diagnosis of hypogonadism, and aligned with a clear monitoring plan.

Disclaimer

This article is for informational purposes only and does not constitute medical advice. Do not start, stop, or change any medication without consulting a qualified healthcare professional.

TRT and Type 2 Diabetes Prevention What 8-Year and RCT Data Show